Business Wire

GREYPARROT/BOLLEGRAAF

Share
Bollegraaf and Greyparrot Forge Strategic AI Partnership to Transform Global Waste Management Industry

Bollegraaf, the world's largest builder of recycling plants, has entered into a strategic partnership with Greyparrot, a pioneer in AI waste analytics, to transform global waste management. As part of the agreement, Bollegraaf will transfer its AI vision business to Greyparrot and also make a cash investment, for a total value of $12.8M, in Greyparrot, obtaining a non-controlling stake in the company. It will also serve as a worldwide distributor and strategic partner for Greyparrot's Analyzer, which currently provides 100% visibility into waste streams at recycling plants across 14 countries using AI camera systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207738309/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Greyparrot Analyzer operating in the Bollegraaf Group test centre. (Photo: Business Wire)

The deal includes Greyparrot acquiring Bollegraaf’s vision-based computing intellectual property (IP) and esteemed AI development team. Greyparrot will also open its first office in mainland Europe in the Netherlands.

With this groundbreaking partnership, both companies aim to retrofit thousands of existing Materials Recovery Facilities (MRFs) and Plastics Recovery Facilities (PRFs) with advanced AI capabilities to significantly boost recycling rates and quantify material emissions. The collaboration will bring forth revolutionary smart recycling plants that are fully automated and agile, unlocking new value in waste streams while diverting millions of tonnes of waste away from landfills, oceans, and incinerators. In a development set to transform waste management, this marks a momentous acceleration in the global shift from a linear to a circular economy. Together, Greyparrot and Bollegraaf commit to developing further products that combine the strengths of both companies to make the vision of fully automated and intelligent sorting facilities a reality.

With over a 50% share in the global recycling plant market, providing turnkey recycling solutions, Bollegraaf is well-positioned to provide the physical infrastructure, while Greyparrot's proven ability to embed AI waste analytics into software and hardware systems adds the essential digital layer. In 2023 alone, Greyparrot’s Analyzer helped facilities analyse more than 25 billion waste objects, characterising them into 70+ categories in real-time to reveal seven layers of data, including material type, financial value, brand, and GHG emissions.

By 2050, the world is expected to generate 3.4 billion tonnes of waste annually. With only around 5,500 facilities handling municipal solid waste currently operating worldwide, there is a critical need to build more next-generation plants and retrofit older ones with new technologies – such as AI – to speed up processing times and improve recycling rates to meet the growing tsunami of waste.

Today, only 1% of waste is monitored in facilities, and even in advanced economies, 40% of waste sorting is done by hand. AI, and the data it unlocks in real-time, will help digitise and automate systems to capture a massive amount of lost financial value. For plastic waste in the U.S. alone, lack of visibility and automation contributes to $80B-$120B being lost a year to landfills and incineration. Greyparrot’s Analyzer gives 100% visibility into waste composition to unlock a new, more intelligent level of insight about waste that Greyparrot calls waste intelligence. With automated, real-time waste monitoring and digitised systems powered by AI, the industry can tackle the issue of 'invisible waste' and transform a traditionally labour-intensive process.

With increased data transparency, waste managers can confidently demonstrate regulatory and contractual compliance. This vital waste data on the post-consumption world will foster unprecedented collaboration across the waste value chain and those influencing it, uniting producers, waste managers and regulators to recover and reuse waste materials more sustainably.

Bollegraaf:

“With 63 years of industry experience, Bollegraaf continues to be a global leader in fully-automated innovative turnkey recycling systems. The future is clear: to further increase recycling rates we need more insight and collaboration across the value chain. We have been looking to implement AI that can power fact-based and automated decision-making to provide our clients with a much more accurate overview of their waste composition and ultimately maximise their ROI,” said Edmund Tenfelde, CEO of Bollegraaf Recycling Solutions. “We are thrilled to make this strategic investment and partner with Greyparrot to bring waste intelligence to both upcoming recycling infrastructure deployments and existing facilities worldwide. We believe that Bollegraaf's comprehensive knowledge of automation of recycling MRF operations, premium equipment quality, and unique engineering expertise empowered with Greyparrot AI systems represent the one-of-a-kind synergy that is destined for success.”

Greyparrot:

“In a world drowning in waste, a large percentage of which is recoverable, the urgency for action has never been greater. It’s time for a revolutionary leap in how we value, capture, and manage our waste. We’re excited to partner with Bollegraaf, and add to our team of experts in artificial intelligence and deep learning, to address this challenge and pave the way for the waste industry's largest rollout of AI to date,” said Mikela Druckman, CEO of Greyparrot. “Getting AI waste analytics in the hands of more plant managers, more quickly, will provide the industry the data-driven insights needed to build and operate smart MRFs that unlock new value from recovered materials and decrease the environmental impact of waste. Collaboration with plant builders and other key players is critical to making this happen, and it's a major reason why Greyparrot is hardware agnostic, making it possible to integrate our platform with all types of systems. Progress in addressing the waste crisis can only happen if we work together and commit to systemic change driven by waste intelligence.”

About Greyparrot

Greyparrot (greyparrot.ai), the leader in AI waste analytics, is applying AI to globally scale recycling and save millions of tonnes of waste from landfills and incinerators. By providing deeper, more intelligent insights about waste stream composition and value, Greyparrot is helping the waste sector recover more value from waste processing lines and reduce the environmental impact of waste.

The company’s waste intelligence platform, including Greyparrot Analyzer and Greyparrot Sync (API), reveals real-time insights on over 70 waste categories across seven layers of data, including financial value, brand, and GHG emissions, captured at multiple locations across a recycling facility. In 2023, Greyparrot analysed over 25 billion waste objects helping drive efficiency to save hundreds of thousands, to millions, of dollars per facility – while diverting millions of tonnes of waste away from landfills, oceans, and incinerators.

Using Greyparrot insights, recycling professionals, plant builders, packaging producers, and FMCG brands can make decisions to help them increase recycling efficiency, comply with recycling regulations, and improve recyclable packaging design.

Click here to see how Greyparrot’s AI waste analytics works

About Bollegraaf

The Bollegraaf Group (bollegraaf.com) is a world-leading expert and innovator in the waste sorting and recycling sector. Bollegraaf’s reputation is based on the unique quality of equipment in terms of separation performance, robustness, and ease of maintenance. A premium quality complemented by the Bollegraaf engineering expertise delivers the best solutions to the specific challenges of each customer. Through continuous and intensive investment in innovation, Bollegraaf offers state-of-the-art recycling solutions for all types of waste streams, from household waste, paper, and plastics up to construction and demolition.

Bollegraaf was founded in the Netherlands in 1961 and comprises the companies: Bollegraaf Recycling Solutions and Lubo Recycling Solutions. The company also has several subsidiaries in Europe. Van Dyk Recycling Solutions is Bollegraaf’s exclusive distributor that operates a highly successful sales office and holds a strong North American presence from its headquarters in Norwalk, U.S.

Bollegraaf’s vision is clear: There is no such thing as waste, only a pool of valuables that need to be sorted, cleaned, and prepared for re-entering a new life cycle.

Click here to see how Bollegraaf creates a world of difference with its solutions

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207738309/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye